P

Paragon Genomics

Develops targeted NGS panels for sequencing

Overview

Paragon Genomics provides custom next-generation sequencing panels, led by its CleanPlex targeted amplicon sequencing technology for fast and accurate results in precision medicine and research. It designs, manufactures, and sells these panels and also offers consultation to help clients plan and implement sequencing projects. Its end-to-end design and production pipeline enables quick turnaround, with uniform coverage across targets and the flexibility to cover single genes or larger panels. Serving researchers, assay developers, IVD and biopharma organizations worldwide, its goal is to enable high-quality targeted sequencing and viral surveillance with reliable panels and strong customer support.

Work here?Claim your company

About Paragon Genomics

Simplify's Rating
Why Paragon Genomics is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsBiotechnologyHealthcare

Company Size

11-50

Company Stage

Series A

Total Funding

$8M

Headquarters

Fremont, CA

Founded

2015

Get referred to Paragon Genomics

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • September 2026 updated AccuFusion RNA Lung Cancer Kit, signaling active product expansion.
  • July 2025 Genecast partnership extends CleanPlex into precision oncology distribution worldwide.
  • July 2024 UK-Ireland Biosecure ID deal expands European reach for CleanPlex sales.

What critics are saying

  • 2017's $8 million Series A is still the latest disclosed financing; capital looks thin.
  • No public evidence of revenue scale beyond estimated $10M-$25M; growth can stall fast.
  • If Illumina or larger rivals bundle cheaper panels, Paragon Genomics loses differentiation and pricing power.

What makes Paragon Genomics unique

  • CleanPlex runs a patented 3-hour, single-tube workflow with 20,000-amplicon scalability.
  • Paragon Genomics delivered 1,600+ custom NGS panels to 300+ labs by October 2026.
  • AccuFusion spans Illumina and Ion Torrent, reducing platform lock-in for customers.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$8M

Below

Industry Average

Funded Over

1 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Below Average

Industry standards

$15M
$8M
$8.2M
$15M
$30M

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Health Savings Account/Flexible Spending Account
  • Flexible Work Hours
  • Paid Vacation
  • Stock Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
GlobeNewswire
Jul 9th, 2024
Paragon Genomics Partners With Biosecure Id To Expand Access To Cleanplex(R) Technology In The Uk And Ireland

FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Paragon Genomics, a California-based leader in advanced amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced an agreement with Biosecure ID to distribute its CleanPlex® products and technology in the United Kingdom and the Republic of Ireland. CleanPlex is a proprietary, ultra-high multiplexed target enrichment technology for NGS-based assays for research and diagnostic testing. Biosecure ID, a new UK-based value-added reseller with expertise in applied genomics, is a for-profit unit of Science Social for Good CIC, an organization dedicated to expanding the availability of locally based genetic research and testing services globally.Tao Chen, Chief Executive Officer of Paragon Genomics, said, “This agreement with the DNA testing visionaries at Biosecure ID caps a year in which we have been expanding the reach of our CleanPlex® products and services via new relationships with a diverse group of distributors serving territories around the globe, including Asia, Europe, Africa and Central America. The UK and Ireland with their advanced life sciences research and clinical communities represent substantial markets for our unique technology, which provides highly advanced and robust targeted resequencing solutions that are easy to use. We look forward to working with the experienced genomics industry experts at Biosecure ID to increase the availability of CleanPlex® products and services in Britain and Ireland and further our mission of advancing precision medicine.”Yogesh Prasad, PhD, MBA, a Co-founder and Director of Biosecure ID, commented, ”As a value-added reseller embodying both a mission and substantial genomics expertise, we are very pleased to partner with Paragon Genomics in the UK and Ireland to distribute their innovative CleanPlex® technology for targeted NGS panel preparation. Our two companies are committed to providing state-of-the-art DNA technologies that advance the utility of genomic testing around the world and are also simple, fast and easy-to-use

MarketScreener
Mar 2nd, 2023
Paragon Genomics Partners with Devyser to Expand CleanPlex Technology Distribution In Italy | MarketScreener

FREMONT - Paragon Genomics, a California -based leader in advanced amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced a partnership with Devyser, a world leader in diagnostic kits and solutions for advanced DNA testing, to distribute its CleanPlex products and technology in Italy, with the option to expand into additional territories.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Paragon Genomics right now.

Find jobs on Simplify and start your career today

We update Paragon Genomics's jobs every few hours, so check again soon!Browse all jobs